Germany’s Capiton eyes single-asset pharma deal – exclusive
Park Hill is understood to be running the process which involves omega-3 producer KD Pharma Bexbach.
16 July 2019•2 mins read
SECONDARIES INVESTOR
Register to unlock this content
Daily global secondaries market news and intelligence- Curated insights to keep you ahead of GP-led and LP-led secondaries
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected fund performance and investor activity data
